Duality Biotherapeutics (HKSE:09606) EV-to-FCF: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09606 Duality Biotherapeutics Inc HKSE:09606
9 GF Score
Price HK$177.80
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Duality Biotherapeutics's Enterprise Value is HK$12,981.4 Mil. Duality Biotherapeutics does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026. Therefore, GuruFocus does not calculate Duality Biotherapeutics's EV-to-FCF at this moment.

The historical rank and industry rank for Duality Biotherapeutics's EV-to-FCF or its related term are showing as below:

HKSE:09606' s EV-to-FCF Range Over the Past 10 Years
Min: -14.73   Med: 80.21   Max: 132.44
Current: -14.19

During the past 4 years, the highest EV-to-FCF of Duality Biotherapeutics was 132.44. The lowest was -14.73. And the median was 80.21.

HKSE:09606's EV-to-FCF is ranked worse than
100% of 314 companies
in the Biotechnology industry
Industry Median: 15.045 vs HKSE:09606: -14.19

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-09-16), Duality Biotherapeutics's stock price is HK$177.80. Duality Biotherapeutics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026. Therefore, GuruFocus does not calculate Duality Biotherapeutics's PE Ratio (TTM) at this moment.

Duality Biotherapeutics  (HKSE:09606) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Duality Biotherapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=177.80/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Duality Biotherapeutics EV-to-FCF Related Terms

Duality Biotherapeutics EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics EV-to-FCF Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EV-to-FCF
0.00 0.00 0.00 79.99

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
EV-to-FCF 0.00 115.52 -14.44

HKSE:09606 vs VRTX, REGN, MRNA: EV-to-FCF Comparison

For the Biotechnology subindustry, Duality Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Duality Biotherapeutics EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Duality Biotherapeutics's EV-to-FCF falls into.


HKSE:09606
9GF Score
Duality Biotherapeutics Inc HKSE:09606
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics EV-to-FCF Calculation

Duality Biotherapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=12981.422/
=

Duality Biotherapeutics Business Description

Other Exchanges 4ZB:Germany
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
9GF Score

Get the complete analysis for HKSE:09606

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$177.80
Price